Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 2/20 | 0.62 |
| ▸ | TFPI | P10646 | 5/20 | 0.62 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.60 |
| ▸ | NPY2R | P49146 | 5/20 | 0.57 |
| ▸ | NPY4R | P50391 | 5/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.57 |
| ▸ | NPY1R | P25929 | 4/20 | 0.57 |
| ▸ | MC4R | P32245 | 2/20 | 0.57 |
| ▸ | MC5R | P33032 | 2/20 | 0.57 |
| ▸ | MC3R | P41968 | 2/20 | 0.57 |
| ▸ | MC1R | Q01726 | 2/20 | 0.57 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.56 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.56 |
| ▸ | CALCR | P30988 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rusalatide SCHEMBL29357268 | 0.99 | TFPI (0.62) | EPHA2TFPICXCR4NPY2RNPY4R | |
| SCHEMBL30415381 | 0.98 | EPHA2 (0.65) | EPHA2TFPINPY2RNPY4RNPY5R | |
| SCHEMBL30415710 | 0.98 | EPHA2 (0.65) | EPHA2TFPINPY2RNPY4RNPY5R | |
| SCHEMBL30415150 | 0.97 | EPHA2 (0.62) | EPHA2TFPICXCR4NPY2RNPY4R | |
| SCHEMBL31473050 | 0.95 | CXCR4 (0.61) | EPHA2TFPICXCR4NPY2RNPY4R | |
| SCHEMBL30415361 | 0.95 | EPHA2 (0.65) | EPHA2TFPICXCR4NPY2RNPY4R | |
| SCHEMBL29390108 | 0.94 | EPHA2 (0.62) | EPHA2TFPICXCR4NPY2RNPY4R | |
| SCHEMBL30186412 | 0.92 | EPHA2 (0.65) | EPHA2TFPINPY2RNPY4RNPY5R | |
| SCHEMBL29392765 | 0.91 | EPHA2 (0.57) | EPHA2TFPICXCR4NPY2RNPY4R | |
| SCHEMBL29389698 | 0.90 | EPHA2 (0.56) | EPHA2TFPICXCR4NPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312463-A1 | AUGMENTED PEPTIDE COMPOSITIONS AND METHODS | Neo7Bioscience, Inc. (US) | 2025-10-09 | — | — | US | claimed |
| US-20250186339-A1 | COMPOSITION FOR INTRAORAL DELIVERY OF BIOLOGICALLY ACTIVE PEPTIDES AND PROTEINS | SCHWARZ JOSEPH (CA) | 2025-06-12 | — | — | US | claimed |
| CN-119979511-A | Expression method of non-proteolytic thrombin peptide TP508 in silk gland of family, product and application thereof | 西部(重庆)科学城种质创制大科学中心 | 2025-05-13 | — | — | CN | claimed |
| CN-118910022-A | Anti-radiation polypeptide and application thereof | 中国人民解放军陆军军医大学 | 2024-11-08 | — | — | CN | claimed |
| WO-2024211447-A1 | TP508 MRNAS | CHRYSALIS BIOTHERAPEUTICS (US) | 2024-10-10 | — | — | WO | claimed |
| WO-2024199558-A1 | METHOD OF PRODUCTION OF FIBERS AND A DEVICE FOR CARRYING OUT THE METHOD | CONTIPRO A.S. (CZ) | 2024-10-03 | — | — | WO | claimed |
| EP-4413184-A1 | METHOD OF PREPARATION OF FIBRES AND DEVICE FOR CARRYING OUT THIS METHOD | Contipro a.s. (CZ) | 2024-08-14 | — | — | EP | claimed |
| EP-3143026-B1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2024-07-10 | — | — | EP | claimed |
| US-20230165943-A1 | TP508 ACUTE THERAPY FOR PATIENTS WITH RESPIRATORY VIRUS INFECTION | CHRYSALIS BIOTHERAPEUTICS, INC. | 2023-06-01 | — | — | US | claimed |
| WO-2023056996-A1 | METHOD OF PREPARATION OF FIBRES AND DEVICE FOR CARRYING OUT THIS METHOD | CONTIPRO A.S. (CZ) | 2023-04-13 | — | — | WO | claimed |
| EP-4132948-A1 | TP508 ACUTE THERAPY FOR PATIENTS WITH RESPIRATORY VIRUS INFECTION | Chrysalis Biotherapeutics (US) | 2023-02-15 | — | — | EP | claimed |
| CN-115001521-A | Mobile police intelligent terminal | 筑泰(深圳)信息技术有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-217037176-U | Double-network-communication multifunctional mobile police intelligent terminal | 筑泰(深圳)信息技术有限公司 | 2022-07-22 | — | — | CN | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-07 | — | — | US | disclosed |
| US-12618174-B2 | Method of production of fibers and a device for carrying out the method | CONTIPRO A.S. (CZ) | 2026-05-05 | — | — | US | disclosed |
| US-20220047775-A1 | DECELLULARIZED TENDON MATRIX METHODS AND USES THEREOF | THE STEADMAN CLINIC AND STEADMAN PHILIPPON RESEARCH INSTITUTE (US) | 2022-02-17 | — | — | US | disclosed |
| EP-3952991-A1 | RUSALATIDE ACETATE COMPOSITIONS | Affirmed Pharma, LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3952991-A1 | RUSALATIDE ACETATE COMPOSITIONS | Affirmed Pharma, LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3952991-A1 | RUSALATIDE ACETATE COMPOSITIONS | Affirmed Pharma, LLC (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | EPHA2 2390/4885TFPI 2300/4885CXCR4 1755/4885 |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NSUN2, SARS1, SNRPE | EPHA2 533/4885TFPI 4754/4885CXCR4 20/4885 |
| US-12618174-B2 | Method of production of fibers and a device for carrying out the method | HCN4, HCN3, PIGS | EPHA2 2492/4885TFPI 371/4885CXCR4 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.